查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863033

依给药途径、剂型、药物类别、通路和最终用户分類的流感治疗药物市场－2025-2032年全球预测

Influenza Medication Market by Route Of Administration, Form, Drug Class, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，流感治疗市场规模将达到 53.9 亿美元，复合年增长率为 5.16%。

关键市场统计数据
基准年 2024 36亿美元
预计年份：2025年 37.9亿美元
预测年份 2032 53.9亿美元
复合年增长率 (%) 5.16%

全面且策略性地介绍影响现代流感治疗决策的临床因素、给药方法和操作重点。

流感治疗环境的特征是临床创新迅速、监管预期不断变化以及医疗保健服务模式不断改变，这些因素共同作用，重新定义了製造商、支付方和医疗服务提供者的策略重点。

本摘要整合了目前的临床重点，例如及时启动抗病毒治疗、抗药性监测和门诊管理等趋势，以及影响药物可近性和使用率的实际情况。它重点阐述了药物类别、给药方法和通路的进步如何与公共卫生紧急准备和季节性需求波动相互作用。透过以连贯的叙述方式呈现临床证据、供应链考量和相关人员的奖励，本导言为决策者提供了一个全面的观点，以完善风险评估、投资优先排序和市场推广计划。

本报告始终强调将临床差异化转化为营运优势（处方集定位、医院库存通讯协定、门诊处方流程）。报告检验了药理特性与分销管道能力之间的相互作用，并指出了实施过程中的摩擦点和机会。最后，本引言为系统性探讨转型变革、价格影响、市场区隔现况、区域动态、竞争行为以及后续的实用建议奠定了基础。

深入检验正在重塑抗病毒治疗模式、获取途径和相关人员优先事项的科学、供应链和治疗路径变革。

流感格局正经历着变革性的转变，这主要得益于科学进步、治疗流程的改进以及对药品供应和配送韧性的重新重视。具有全新作用机制的新型抗病毒药物正在改变治疗模式，而对快速诊断和门诊治疗的重视也在改变着治疗方法的处方和分发地点及方式。

同时，随着各组织寻求降低中断风险，生产弹性和策略采购也成为重中之重。吸入和口服製剂的改进以及标靶分子疗法的进步，正迫使支付方和医疗服务提供者重新评估治疗流程。因此，相关人员越来越重视真实世界疗效和抗药性特征，而非传统的疗效终点，这正在影响药物上市决策和临床指引。

此外，数位医疗技术和不断发展的分销管道正在推动以患者为中心的医疗保健模式。远距医疗、药品宅配服务和整合式照护路径支援更早启动治疗，并可能显着影响需求模式和库存管理。鑑于这些变化，企业必须采取整合的商业化策略，协调其开发平臺、监管策略和通路拓展，以实现并维持临床和市场相关性。

深入检验2025 年关税政策带来的供应链趋势和筹资策略调整，这些政策正在重塑跨境治疗药物采购和库存策略。

2025年实施的新关税政策为医药产业的跨境供应链和筹资策略带来了显着的复杂性。关税调整加剧了国际采购成本的影响，迫使生产者和经销商重新评估其生产基地、整合供应合约并重新评估本地库存策略，以维持服务水准并确保产品流通的稳定性。

为此，一些机构正在加快关键製造流程的在地化或对替代供应商进行资格认证，以降低关税波动带来的风险。另一些机构则正在与下游合作伙伴重新谈判商业条款，以便在价值链中更公平地分摊新增成本。这些调整凸显了弹性合约、双重采购和库存缓衝的重要性，它们能够帮助吸收关税引起的成本波动，同时确保临床供应不会中断。

此外，采购团队和政策相关人员在重新评估竞标和采购框架，以反映新的到岸成本实际情况。对市场参与企业而言，实际影响包括：在国际物流中，情境规划和压力测试的重要性日益凸显；以及对监管协调的重新关注，这将有助于简化成品製剂和原料药的跨境运输。最终，海关情势凸显了供应链韧性作为商业规划关键要素的策略价值。

将给药途径、製剂细微差别、药物类别区分、分销管道和最终用户路径等因素与策略决策槓桿联繫起来的详细细分洞察

详细的細項分析揭示了给药途径、剂型、药物类别、分销管道和最终用户环境的不同临床、商业性和营运影响，这些因素共同决定了产品定位和通路策略。

在评估给药途径时，利害关係人应考虑以下几点：吸入给药可使药物快速到达肺部标靶；静脉注射是重症监护和住院治疗的重要选择；口服给药则方便门诊病人使用。口服给药方面，混悬液和药片的差异会影响患者的遵从性、儿童用药剂量和配药流程。就剂型而言，注射剂仍然是住院治疗的核心，而吸入粉剂则用于门诊给药。混悬剂可灵活调整儿童和吞嚥困难患者的用药剂量，而片剂则涵盖了金刚烷胺、巴洛沙韦酯、奥司他韦和利马他定等多种药物，这对处方趋势和库存管理具有重要意义。

从药物类别角度来看，核酸内切酶抑制剂具有新颖的作用机制，影响抗药性与合併用药策略。 M2离子通道抑制剂，包括金刚烷胺和利巴韦林，由于其特定的历史抗药性和安全性特征，目前在某些特定情况下使用受到限制。神经氨酸酶抑制剂，包括奥司他韦、帕拉米韦和扎那米韦，是目前抗病毒治疗的基石，尤其是在能够早期给药的情况下。通路分析突显了医院药房作为患者照护和急诊护理基石的重要作用；在线药房为患者提供直接便捷的用药途径；以及零售药房作为季节性需求和药剂师主导的咨询服务的主要患者接触点。最后，终端使用者细分突显了居家照护在早期启动治疗和依从性支持方面日益增长的重要性；医院在急性护理和重症病例管理方面的重要性；以及门诊诊所作为诊断、启动治疗和后续观察的关键枢纽的重要性。每种环境都会影响库存管理政策、包装选择和病患教育需求。

对这些相互关联的细分维度进行整体考虑，将指导商业化选择，从包装和分发形式到通路伙伴关係和有针对性的医学事务计划，并且在设计上市和生命週期策略时应进行整体考虑。

在製定打入市场策略，要从全面的区域观点出发，协调美洲、欧洲、中东和非洲以及亚太地区的监管、分销和临床实践差异。

区域趋势持续对全球流感药物的取得、监管和采用模式产生决定性影响，因此需要製定细緻入微、因地制宜的策略，使临床证据与分销能力和支付方的期望相一致。

在美洲，完善的门诊病人基础设施、一体化的零售药房网路和强大的居家医疗服务为口服抗病毒药物和以药房主导的治疗启动途径创造了机会。诊断的可近性和支付方的覆盖模式进一步影响药物的普及趋势。在欧洲、中东和非洲，不同的监管路径和不同的报销体係要求采取灵活的实施方案，兼顾各国的药品目录和区域临床指南。同时，该地区的一些市场正在投资扩大住院床位并实现供应链现代化，以加强应对疫情的能力。在亚太地区，数位健康工具的快速普及、对本地生产投资的增加以及社区护理模式的高普及率，都为多元化的分销策略提供了支持，该策略可以根据当地的处方习惯，优先提供吸入剂和口服液剂型。

在所有地区，相关人员必须调整产品定位，以反映诊断基础设施、药师执业范围和支付体系的差异。此外，以抗菌药物管理和抗药性监测为重点的区域政策也日益影响治疗方案和处方集决策。因此，采取因地制宜的方法，使临床讯息、供应策略和通路合作与当地系统实际情况相符，对于确保药物的持续可及性和使用率至关重要。

透过策略性企业行动和能力投资，在研发、製造、数位化伙伴关係以及通路特定的商业化模式方面实现差异化。

企业行动和策略姿态决定了流感治疗领域药物发现、开发、生产和商业化活动的竞争格局。

主要企业正优先建构兼顾近期商业机会与对新型作用机制和联合治疗进行长期投资的产品组合。生物製药开发商、专业製造商和诊断服务提供者之间的策略联盟正在加速整合价值提案，将抗病毒疗法与快速就地检验和患者分流服务相结合。在生产方面，企业正投资于模组化、多地点的生产能力，以提高灵活性并降低对单一供应来源的依赖风险。同时，品质和供应连续性计划在董事会层面也变得日益重要。

在商业方面，他们正在完善主导细分市场为导向的市场推广模式，以优化针对医院处方集委员会、零售药房网路和数位健康平台的讯息。医学事务团队在生命週期管理中发挥核心作用，提供实证医学证据和真实世界结果研究，以帮助解决抗药性问题和疗效比较问题。一些机构也正在探索差异化包装、病患援助解决方案和依从性技术，以增强门诊病人的连续性和价值。这些企业层面的努力正在重塑竞争优势，使其从纯粹以产品为中心的差异化转向涵盖诊断、供应稳定性和管道驱动的患者获取途径的整合解决方案。

为领导者提供切实可行的、优先排序的建议，以协调临床差异化与供应链韧性、通路优化和循证市场进入策略。

我们鼓励产业领导者采取一系列切实可行的倡议，将临床差异化、营运韧性和通路优化相结合，以帮助创造价值并改善患者预后。

首先，将抗药性监测和真实世界疗效终点纳入研发和上市后证据计划，以确保治疗定位能够适应不断变化的临床实践。其次，推动供应链多元化，并对关键供应商进行在地化合格，以最大限度地降低关税和物流衝击带来的风险。双重采购和应急库存应纳入情境规划。第三，设计包装和剂型时，应充分考虑居家医疗、医院和门诊等不同环境下最终使用者的需求，优先考虑儿童和老年患者的易用性。第四，加强与诊断服务提供者和数位平台的合作，加速治疗启动，并制定能够提高患者依从性和治疗效果的综合护理路径。第五，制定符合当地医保报销体系的市场进入策略，使临床文件符合支付方的证据要求，并酌情儘早与卫生技术评估机构接洽。

最后，需要投资于有针对性的商业性能力，例如药房协作团队、数位化病患援助和按绩效付费合约方面的专业知识，才能将临床价值转化为处方集的采纳和持续采纳。透过实施这些建议，管理者可以提高流感药物的临床和商业性绩效，同时最大限度地降低营运风险。

本报告的调查方法透明且以证据主导，结合了专家访谈、系统性的二手研究和情境三角验证，以检验研究结果和建议。

本报告的调查方法结合了多方面的证据综合、专家对话和系统性检验，以确保得出可靠的实用结论。

初步研究包括对临床医生、药房主任、供应链主管和支付方代表进行深度访谈，以解读临床实践、处方集使用情况和采购趋势。次要研究包括对同行评审的临床文献、监管指导文件、公共卫生建议和产品标籤进行系统性回顾，以深入了解药物作用机制和安全性概况。分析还整合了通路和临床试验点的营运数据，以将临床特征与实际应用中的挑战联繫起来。

研究结果透过跨部门研讨会和敏感度分析进行三角验证，以检验假设并确定替代情境。对于存在不确定性，例如抵抗趋势的变化和政策的调整，研究明确提出了保留意见，并记录了方法选择，以确保透明度。最终形成的方法论优先考虑基于证据的解释、相关人员的检验以及考虑情境的建议，为短期战术性选择和长期策略规划提供参考。

最终整合凸显了临床创新、供应链韧性和分销策略的整合执行，以确保患者能够获得治疗并展现患者获益。

总之，流感治疗生态系统正处于一个转折点，科学创新、不断发展的通路和供应韧性正在汇聚，重新定义价值链上相关人员的策略要务。

该报告的综合视角强调，成功的专案需要将临床差异化和营运前瞻性相结合：将新颖的作用机制和易于使用的製剂与稳健的分销策略和循证实践计划相结合。由于区域差异和关税，供应压力日益复杂，因此，灵活选择製造地并与支付方和医疗服务提供者密切合作至关重要。积极整合诊断伙伴关係、加强与药房的合作并优先考虑真实世界证据生成的公司，将更有利于展现产品价值，并确保在各种医疗环境中实现永续的药物可及性。

归根结底，前进的方向在于整合实施——协调研发选择、商业模式和供应链策略，以加快及时获取药物，管理抗药性风险，并为患者和医疗保健系统带来可衡量的收益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 采用mRNA平台技术开发通用流感疫苗
  • 将数位健康工具整合到流感治疗依从性监测中
  • 非处方抗病毒药物和快速家用检测套组的结合推动了成长
  • 针对高风险患者流感病毒蛋白的单株抗体疗法取得进展
  • 製药公司与生技Start-Ups进行策略合作，共同开发下一代流感疫苗
  • 引入人工智慧驱动的预测模型，用于优化季节性流感疫苗株的选择
  • 增加对有针对性的流感预防药物的投资，以满足儿童和老年人的需求。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依给药途径分類的流感药物市场

  • 吸入
  • 静脉注射
  • 口服
    • 暂停
    • 药片

第九章 流感药物市场（依剂型划分）

  • 注射
  • 粉末吸入剂
  • 暂停
  • 药片
    • 金刚烷胺
    • 巴洛沙韦酯
    • 奥司他韦
    • 金刚烷胺

第十章 流感药物市场（依药物类别划分）

  • 核酸内切酶抑制剂
  • M2离子通道抑制剂
    • 金刚烷胺
    • 金刚烷胺
  • 神经氨酸酶抑制剂
    • 奥司他韦
    • 帕拉米韦
    • 扎那米韦

第十一章 流感药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 流感药物市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 门诊部

第十三章 各地区流感药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 流感药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国流感药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • CSL Seqirus Pty Ltd
    • Sanofi Pasteur SA
    • AstraZeneca plc
    • Shionogi & Co., Ltd
    • BioCryst Pharmaceuticals, Inc.
    • Cipla Ltd
    • Teva Pharmaceutical Industries Ltd
    • Sandoz International GmbH
Product Code: MRR-F6513A06BE18

The Influenza Medication Market is projected to grow by USD 5.39 billion at a CAGR of 5.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.60 billion
Estimated Year [2025] USD 3.79 billion
Forecast Year [2032] USD 5.39 billion
CAGR (%) 5.16%

A comprehensive and strategic introduction framing clinical drivers, delivery modalities, and operational imperatives that shape modern influenza therapeutic decision-making

The influenza therapeutic environment is characterized by rapid clinical innovation, evolving regulatory expectations, and shifting patterns of care delivery that together redefine strategic priorities for manufacturers, payers, and providers.

This summary synthesizes the current clinical imperatives-such as timely antiviral initiation, resistance monitoring, and outpatient management trends-alongside the operational realities that shape access and uptake. It highlights how advances in drug classes, delivery modalities, and distribution channels are intersecting with public health preparedness and seasonal demand variability. By placing clinical evidence, supply chain considerations, and stakeholder incentives in one coherent narrative, the introduction equips decision-makers with a holistic vantage point from which to assess risk, prioritize investment, and refine go-to-market planning.

Throughout the report, emphasis is placed on translating clinical differentiation into operational levers: formulary positioning, hospital stocking protocols, and outpatient prescribing workflows. The interplay between pharmacological attributes and channel capabilities is explored to identify friction points and opportunities for adoption. Ultimately, this introduction lays the foundation for a structured exploration of transformative shifts, tariff impacts, segmentation realities, regional dynamics, competitive behaviors, and practical recommendations that follow.

An in-depth review of scientific, supply chain, and care pathway shifts that are reshaping antiviral treatment patterns, access models, and stakeholder priorities

The influenza landscape is undergoing transformative shifts driven by scientific advances, care pathway evolution, and a renewed focus on resilience in supply and delivery. Emerging antiviral classes with novel mechanisms of action are changing treatment paradigms, while the renewed emphasis on rapid diagnostics and outpatient care is reshaping where and how therapies are prescribed and dispensed.

Concurrently, manufacturing agility and strategic sourcing have moved to the forefront as organizations seek to mitigate disruption risks. The convergence of improved inhalation and oral formulations, coupled with targeted molecular therapies, is prompting payers and providers to reassess treatment algorithms. As a result, stakeholders are increasingly prioritizing real-world effectiveness and resistance profiles over traditional efficacy endpoints, thereby influencing formulary decisions and clinical guidelines.

Additionally, digital health enablers and evolving distribution channels are facilitating more patient-centric models of care. Remote consultations, pharmacy home delivery services, and integrated care pathways support earlier initiation of therapy, which can materially affect demand patterns and stock management. Taken together, these shifts require companies to adopt integrated commercialization approaches that align R&D pipelines, regulatory strategies, and channel engagement to capture and sustain clinical and market relevance.

A detailed examination of 2025 tariff-driven supply chain dynamics and procurement adaptations that are reshaping cross-border sourcing and inventory strategies for therapeutics

The introduction of new tariff policies in 2025 has introduced material complexity into cross-border pharmaceutical supply chains and procurement strategies. Tariff adjustments have amplified the cost implications of international sourcing, prompting manufacturers and distributors to reassess production footprints, aggregate supply agreements, and local inventory strategies in order to preserve service levels and maintain predictable product flows.

In response, some organizations have accelerated localization of critical manufacturing steps or qualified alternate suppliers to reduce exposure to tariff volatility. Others have renegotiated commercial terms with downstream partners to distribute incremental costs more equitably across the value chain. These adaptations have emphasized the importance of flexible contracting, dual-sourcing, and inventory buffers to absorb tariff-induced cost movements without disrupting clinical availability.

Moreover, procurement teams and policy stakeholders are re-evaluating tender and purchasing frameworks to reflect new landed-cost realities. The practical consequence for market participants is a heightened emphasis on scenario planning and stress testing for international logistics, as well as a renewed focus on regulatory harmonization that can simplify cross-border movement of finished dosage forms and APIs. Ultimately, the tariff landscape has underscored the strategic value of supply chain resilience as an integral component of commercial planning.

Detailed segmentation insights connecting route of administration, formulation nuances, drug class differentiation, distribution channels, and end-user pathways to strategic decision levers

A granular segmentation lens reveals distinctive clinical, commercial, and operational implications across routes, forms, drug classes, distribution channels, and end-user settings that collectively inform product positioning and channel strategy.

When evaluating Route Of Administration, stakeholders must consider Inhalation as a modality that supports rapid pulmonary delivery for targeted effect, Intravenous as a critical option for severe cases and inpatient settings, and Oral treatments that cater to outpatient convenience; within Oral, the differentiation between Suspension and Tablet formulations affects adherence, pediatric dosing, and dispensing workflows. In terms of Form, Injection remains central to hospitalized care pathways while Powder Inhaler supports ambulatory administration; Suspension formulations enable flexible dosing for children and patients with swallowing difficulties, and Tablet formats encompass a portfolio that includes Amantadine, Baloxavir Marboxil, Oseltamivir, and Rimantadine with important implications for prescribing preferences and stock management.

From a Drug Class perspective, Endonuclease Inhibitors represent a newer mechanism with implications for resistance management and combination strategies; M2 Ion Channel Inhibitors encompass Amantadine and Rimantadine and carry a specific historical resistance and safety profile that limits their contemporary use in certain contexts; Neuraminidase Inhibitors include Oseltamivir, Peramivir, and Zanamivir and remain a cornerstone of current antiviral toolkits, particularly where early administration is feasible. Distribution Channel analysis highlights Hospital Pharmacy as the fulcrum for inpatient care and emergency treatment, Online Pharmacy as an accelerating conduit for direct-to-patient access and convenience, and Retail Pharmacy as the primary patient-facing touchpoint for seasonal demand and pharmacist-led counseling. Lastly, End User segmentation underscores that Home Care is increasingly important for early treatment initiation and adherence support, Hospitals represent acute care and severe case management, and Outpatient Clinics serve as critical points for diagnosis, initiation of therapy, and follow-up-each setting shaping stocking decisions, packaging choices, and patient education needs.

Taken together, these interlocking segmentation dimensions guide commercialization choices, from packaging and dispensing formats to channel partnerships and targeted medical affairs programs, and should be considered holistically when designing launch and lifecycle strategies.

Comprehensive regional perspective that aligns regulatory, distribution, and clinical practice differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry strategies

Regional dynamics continue to exert a defining influence on access, regulation, and adoption patterns across the global influenza therapeutic landscape, requiring nuanced regional strategies that align clinical evidence with distribution capabilities and payer expectations.

In the Americas, established outpatient infrastructures, integrated retail pharmacy networks, and strong home-care services create opportunities for orally administered antivirals and pharmacy-led initiation pathways; diagnostic availability and payer coverage models further shape adoption dynamics. In Europe, Middle East & Africa, variable regulatory pathways and heterogeneous reimbursement systems necessitate flexible launch approaches that account for national formularies and local clinical guidelines, while some markets in the region are investing in expanded inpatient capacities and supply chain modernization to strengthen pandemic preparedness. In the Asia-Pacific region, fast-moving adoption of digital health tools, rising investments in local manufacturing, and a high prevalence of community-based care models support diversified distribution strategies that can emphasize both inhalation and oral solution access depending on local prescribing habits.

Across all regions, stakeholders should calibrate product positioning to reflect differences in diagnostic infrastructure, pharmacist scope of practice, and payer arrangements. Moreover, regional policy initiatives focused on antimicrobial stewardship and resistance surveillance are increasingly shaping therapeutic choice and formulary decisions. Consequently, a regionally adaptive approach-one that aligns clinical messaging, supply strategies, and channel engagement with local system realities-will be essential for sustained access and uptake.

Strategic company behaviors and capability investments that are driving differentiation across R&D, manufacturing, digital partnerships, and channel-focused commercialization models

Company behaviors and strategic postures are defining competitive dynamics across discovery, development, manufacturing, and commercialization activities in the influenza therapeutics arena.

Leading firms are prioritizing portfolios that balance near-term commercial opportunities with longer-term investments in novel mechanisms and combination therapies. Strategic partnerships between biologics developers, specialty manufacturers, and diagnostic providers are accelerating integrated value propositions that tie antiviral therapies to rapid point-of-care testing and patient triage services. On the manufacturing front, firms are investing in modular and multi-site production capabilities to enhance flexibility and reduce single-source vulnerabilities, while quality and supply continuity programs are being elevated to board-level attention.

Commercially, companies are refining segmentation-driven go-to-market models that tailor messaging to hospital formulary committees, retail pharmacy networks, and digital health platforms. Medical affairs teams are increasingly central to lifecycle management, providing evidence generation and real-world outcomes studies that support positioning in the face of resistance concerns and comparative effectiveness questions. Some organizations are also exploring differentiated packaging, patient support solutions, and adherence technologies to strengthen outpatient persistence and therapeutic value. Collectively, these company-scale actions are reshaping competitive advantage from purely product-centric differentiation toward integrated solutions that span diagnostics, supply robustness, and channel-enabled patient access.

Actionable and prioritized recommendations for leaders to align clinical differentiation with supply resilience, channel optimization, and evidence-driven market access strategies

Industry leaders should adopt a set of pragmatic, actionable moves that align clinical differentiation with operational resilience and channel optimization to capture value and support improved patient outcomes.

First, embed resistance surveillance and real-world effectiveness endpoints into development and post-launch evidence plans so that therapeutic positioning responds to evolving clinical practice. Second, pursue supply chain diversification and local qualification of key suppliers to minimize exposure to tariff and logistics shocks; dual-sourcing and contingency inventories should be part of scenario planning. Third, design packaging and dosing formats that reflect end-user needs across home care, hospitals, and outpatient clinics, ensuring that pediatric and geriatric usability considerations are prioritized. Fourth, cultivate partnerships with diagnostic providers and digital platforms to accelerate timely initiation of therapy and to create bundled care pathways that improve adherence and outcomes. Fifth, tailor regional market access strategies to local reimbursement frameworks, aligning clinical dossiers with payer evidence requirements and engaging early with health technology assessment bodies when applicable.

Finally, invest in targeted commercial capabilities-such as pharmacy engagement teams, digital patient support, and outcome-based contracting expertise-that can translate clinical value into formulary acceptance and sustained uptake. By implementing these recommendations, leaders can minimize operational risk while enhancing the clinical and commercial performance of influenza therapeutics.

A transparent, evidence-driven methodology integrating primary expert interviews, systematic secondary research, and scenario triangulation to validate findings and recommendations

The research methodology underpinning this report combines multi-source evidence synthesis, expert engagement, and systematic validation to ensure robust and actionable conclusions.

Primary research included in-depth interviews with clinicians, pharmacy directors, supply chain executives, and payer representatives to ground interpretations of clinical practice, formulary behavior, and procurement dynamics. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, public health advisories, and product labeling to corroborate mechanism-of-action insights and safety profiles. The analysis also integrated operational data on distribution channels and care settings to link clinical attributes with real-world execution challenges.

Findings were triangulated through cross-functional workshops and sensitivity analysis to test assumptions and surface alternative scenarios. Where uncertainties existed-such as evolving resistance trends or policy shifts-clear caveats were included and methodological choices were documented to support transparency. The result is a methodological approach that prioritizes evidence-backed interpretation, stakeholder validation, and scenario-aware recommendations to inform both near-term tactical choices and longer-term strategic planning.

A conclusive synthesis emphasizing integrated execution across clinical innovation, supply resilience, and channel strategies to secure access and demonstrable patient benefit

In conclusion, the influenza therapeutic ecosystem is at an inflection point where scientific innovation, channel evolution, and supply resilience converge to redefine strategic imperatives for stakeholders across the value chain.

The synthesis presented here underscores that successful programs will marry clinical differentiation with operational foresight: aligning novel mechanisms and user-friendly formulations with robust distribution strategies and evidence-generation plans. Regional nuances and tariff-driven supply pressures add layers of complexity that necessitate adaptive manufacturing footprints and close collaboration with payers and providers. Companies that proactively integrate diagnostic partnerships, strengthen pharmacy engagement, and prioritize real-world evidence generation will be better positioned to demonstrate value and secure sustainable access in diverse care settings.

Ultimately, the path forward is one of integrated execution-where R&D choices, commercial models, and supply chain strategies are orchestrated to accelerate timely access, manage resistance risk, and deliver measurable benefits for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of mRNA platform technology for universal influenza vaccine development
  • 5.2. Integration of digital health tools in influenza treatment adherence monitoring
  • 5.3. Growth of over-the-counter antiviral medications combined with rapid home testing kits
  • 5.4. Advances in monoclonal antibody therapies targeting influenza viral proteins among high-risk patients
  • 5.5. Strategic partnerships between pharmaceutical companies and biotech startups for next-generation flu vaccines
  • 5.6. Implementation of AI-driven forecasting models for selecting optimal seasonal influenza vaccine strains
  • 5.7. Rising investment in targeted influenza prophylactics addressing pediatric and geriatric population needs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Medication Market, by Route Of Administration

  • 8.1. Inhalation
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Suspension
    • 8.3.2. Tablet

9. Influenza Medication Market, by Form

  • 9.1. Injection
  • 9.2. Powder Inhaler
  • 9.3. Suspension
  • 9.4. Tablet
    • 9.4.1. Amantadine
    • 9.4.2. Baloxavir Marboxil
    • 9.4.3. Oseltamivir
    • 9.4.4. Rimantadine

10. Influenza Medication Market, by Drug Class

  • 10.1. Endonuclease Inhibitors
  • 10.2. M2 Ion Channel Inhibitors
    • 10.2.1. Amantadine
    • 10.2.2. Rimantadine
  • 10.3. Neuraminidase Inhibitors
    • 10.3.1. Oseltamivir
    • 10.3.2. Peramivir
    • 10.3.3. Zanamivir

11. Influenza Medication Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Influenza Medication Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Outpatient Clinics

13. Influenza Medication Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Influenza Medication Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Influenza Medication Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Hoffmann-La Roche AG
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. CSL Seqirus Pty Ltd
    • 16.3.4. Sanofi Pasteur SA
    • 16.3.5. AstraZeneca plc
    • 16.3.6. Shionogi & Co., Ltd
    • 16.3.7. BioCryst Pharmaceuticals, Inc.
    • 16.3.8. Cipla Ltd
    • 16.3.9. Teva Pharmaceutical Industries Ltd
    • 16.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA INFLUENZA MEDICATION MARKE